Platensimycin
From Wikipedia, the free encyclopedia
Platensimycin is an experimental new drug being trialed in an effort to combat MRSA.[1] Manufactured by a strain of Streptomyces platensis, it represents a previously unknown class of antibiotics, which acts by blocking enzymes involved in the synthesis of fatty acids,[2] which bacteria need to construct cell membranes (β-ketoacyl-ACP synthase I/II (FabF/B)). Currently being researched by Merck.
Recently, a first total synthesis of racemic platensimycin has been published.[3]
[edit] References
- ^ Jun Wang et al, Platensimycin is a selective FabF inhibitor with potent antibiotic properties, Nature 441, 358-361 (18 May 2006) PMID 16710421
- ^ Dieter Häbich, Franz von Nussbaum, ChemMedChem 2006, 1, 951–954. Platensimycin, a new antibiotic and "superbug challenger" from nature. PMID 16952137
- ^ K. C. Nicolaou, A. Li, D. J. Edmonds, Angew. Chem. 2006, 118, 7244 – 7248; Angew. Chem. Int. Ed. 2006, 45, 7086 – 7090. PMID 17013803
[edit] External links
- BBC News
- Science news stories on Platensimycin
- Abstract in Nature: Platensimycin is a selective FabF inhibitor with potent antibiotic properties
 |
This medical article is a stub. You can help Wikipedia by expanding it. |
